Announcements
- Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
- Idorsia announces changes to Idorsia Executive Committee and Board of Directors
- Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
- Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
- Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
- Bondholders approve amended terms of the 2024 convertible bonds
- Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
- JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
- Idorsia publishes an invitation to a bondholder meeting
- Idorsia publishes a Financial Status required for an upcoming bondholder meeting
More ▼
Key statistics
As of last trade, Idorsia Ltd (0RQE:LSE) traded at 2.24, 73.11% above the 52 week low of 1.29 set on Jan 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.26 |
---|---|
High | -- |
Low | -- |
Bid | 2.16 |
Offer | 2.39 |
Previous close | 2.24 |
Average volume | 8.42k |
---|---|
Shares outstanding | 188.97m |
Free float | 120.68m |
P/E (TTM) | -- |
Market cap | 425.18m CHF |
EPS (TTM) | -0.3534 CHF |
Data delayed at least 20 minutes, as of May 28 2024 15:57 BST.
More ▼